{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:35:56Z","timestamp":1791430556194,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.transci.2018.07.015","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T12:41:44Z","timestamp":1533127304000},"page":"661-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study"],"prefix":"10.1016","volume":"57","author":[{"given":"Federico","family":"Bigazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Berretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenti","family":"Maria Grazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-7052","authenticated-orcid":false,"given":"Giovanni B.","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"D\u2019Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Dal Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascia","family":"Pianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ripoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rafanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Sampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2018.07.015_bib0005","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2018.07.015_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1476-511X-13-59","article-title":"Lipoprotein(a) is associated with necrotic core progression of nonculprit coronary lesions in statin-treated patients with angina pectoris","volume":"13","author":"Nozue","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.transci.2018.07.015_bib0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.transci.2018.07.015_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2014.05.944","article-title":"Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting","volume":"235","author":"Ezhov","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.transci.2018.07.015_bib0025","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"Lipid Res"},{"key":"10.1016\/j.transci.2018.07.015_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00508-010-1318-0","article-title":"Lipoprotein (a) predicts progression on artery intima-media thickening in patients type 2 diabetes: A four-year follow-up","volume":"122","author":"Boras","year":"2010","journal-title":"Wien Klin Wochenschr"},{"issue":"12","key":"10.1016\/j.transci.2018.07.015_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-016-0622-1","article-title":"Emerging Therapeutic Options for Lowering of Lipoprotein(a): implications for prevention of cardiovascular disease","volume":"18","author":"Boffa","year":"2016","journal-title":"Curr Atheroscler Rep"},{"issue":"10057","key":"10.1016\/j.transci.2018.07.015_bib0040","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.transci.2018.07.015_bib0045","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.21037\/jtd.2017.01.40","article-title":"Lipoprotein(a) and inhibitors of proprotein convertase subtilisin\/kexin type 9","volume":"9","author":"Kotani","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.transci.2018.07.015_bib0050","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/17425255.2015.1075506","article-title":"PCSK9 inhibitors--past, present and future","volume":"11","author":"Reiner","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.transci.2018.07.015_bib0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.transci.2018.07.015_bib0060","first-page":"413","article-title":"Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"14","key":"10.1016\/j.transci.2018.07.015_bib0065","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2018.07.015_bib0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11789-015-0071-3","article-title":"Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease","volume":"10","author":"Heigl","year":"2015","journal-title":"Clin Res Cardiol Suppl"},{"issue":"3","key":"10.1016\/j.transci.2018.07.015_bib0075","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","author":"Jaeger","year":"2009","journal-title":"A. Nat Clin Pract Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.transci.2018.07.015_bib0080","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.transci.2018.07.015_bib0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"C Atheroscler Suppl"},{"key":"10.1016\/j.transci.2018.07.015_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosissup.2015.02.034","article-title":"Actual situation of lipoprotein apheresis in Saxony in 2013","volume":"18","author":"Emmrich","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.transci.2018.07.015_bib0095","first-page":"349","article-title":"Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection","volume":"9","author":"Julius","year":"2016","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.transci.2018.07.015_bib0100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosissup.2017.05.047","article-title":"Most significant reduction of cardiovascular events in patients undergoing lipoprotein apheresis due to raised Lp(a) levels - A multicenter observational study","volume":"30","author":"Schatz","year":"2017","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"10.1016\/j.transci.2018.07.015_bib0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.transci.2018.07.015_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1744-9987.2012.01142.x","article-title":"Italian multicenter study on low-density lipoprotein apheresis working group","volume":"17","author":"Stefanutti","year":"2013","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.transci.2018.07.015_bib0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/met.2011.0026","article-title":"Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk","volume":"9","author":"Enkhmaa","year":"2011","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.transci.2018.07.015_bib0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11789-015-0074-0","article-title":"Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects","volume":"10","author":"Schmitz","year":"2015","journal-title":"Clin Res Cardiol Suppl"},{"issue":"9","key":"10.1016\/j.transci.2018.07.015_bib0125","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"for the Pro(a) LiFe-Study Group. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease. Prospective 5 years of follow-up and apo(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.transci.2018.07.015_bib0130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.transci.2018.07.015_bib0135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosissup.2017.05.004","article-title":"Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity","volume":"30","author":"Pokrovsky","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.transci.2018.07.015_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5339\/gcsp.2014.3","article-title":"The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina","volume":"1","author":"Khan","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.transci.2018.07.015_bib0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.transci.2009.10.003","article-title":"Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care","volume":"42","author":"Stefanutti","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.transci.2018.07.015_bib0150","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-Based approach from the writing committee of the american society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218302386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050218302386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T07:50:00Z","timestamp":1543823400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050218302386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1473050218302386"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2018.07.015","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2018.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}